About
About us
Business Model
Team
Scientific Advisors
Sevuparin
About Sevuparin
Actions of sevuparin
Further reading
Research & Development
Pipeline
About Sepsis
About anemia and CKD
About severe malaria
Sevuparin and sepsis
Sevuparin and hepcidin
Sevuparin and malaria
Investors
IPO 2021/ TO1 2022
Issues 2023
Share
News
Financial Reports
Presentations
Calendar
Corporate Governance
Analyst Coverage
News
Contact
EN
SV
All Press Releases
ALL PRESS RELEASES 2021
Jun 11, 2021
Modus Therapeutics and Imperial College London Sign Clinical Collaboration Targeting Severe Malaria
>
May 6, 2021
Modus Therapeutics publishes interim report for Q1
>
Apr 20, 2021
Notice to Annual General Meeting in Modus Therapeutics Holding AB
>
Mar 15, 2021
Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market
>
Mar 12, 2021
Modus Therapeutics – Claes Lindblad Joins as Chief Financial Officer
>
Mar 10, 2021
Modus Therapeutics Announces New Strategy for the Clinical Development of Sevuparin as a Potential Treatment for Sepsis/Septic shock
>
